PDF(Pubmed)
Abstract：
The treatment of canine leishmaniosis commonly involves meglumine antimoniate with allopurinol or miltefosine with allopurinol. This study aims to compare the clinical and clinicopathological efficacy at 28-30 days of conventional dosing regimens for both treatments using the critically appraised topic methodology. A comprehensive search across three databases (PubMed, CAB Abstracts, and Web of Science) from March 2004 to September 2023 yielded 16 relevant articles, encompassing 325 ogs treated with meglumine antimoniate and allopurinol, and 273 dogs treated with miltefosine and allopurinol. The findings indicated a significantly higher rate of complete clinical cure in the group treated with meglumine antimoniate and allopurinol. Most dogs in both groups exhibited improvement in clinicopathological alterations after one month of treatment. No significant difference was observed in the number of dogs that showed a negative Leishmania qPCR between the two groups, one month post-treatment. However, quantitative serology results were not commonly reported in the available data and therefore this aspect could not be compared.
摘要：
犬利什曼病的治疗通常涉及用别嘌呤醇或米替福辛与别嘌呤醇的锑葡甲胺。本研究旨在使用严格评估的主题方法比较两种治疗方法的28-30天常规给药方案的临床和临床病理疗效。跨三个数据库的全面搜索(PubMed，CAB文摘,和WebofScience)从2004年3月到2023年9月发表了16篇相关文章，包括325个OGS用葡甲胺锑酸盐和别嘌呤醇治疗，和273只狗用米替福辛和别嘌呤醇治疗。研究结果表明，在使用锑酸葡甲胺和别嘌呤醇治疗的组中，完全临床治愈率明显更高。治疗一个月后，两组中的大多数狗的临床病理改变均得到改善。两组间显示利什曼原虫qPCR阴性的狗的数量没有观察到显著差异,治疗后一个月。然而,现有数据中通常不报道定量血清学结果,因此无法对这方面进行比较.
